Effects of ginger on serum lipids and lipoproteins in peritoneal dialysis patients: A randomized controlled trial

Peritoneal Dialysis International

Volumn 36, Issue 2, 2016, Pages 140-145

  Tabibi, Hadi ^a   Imani, Hossein ^a   Atabak, Shahnaz ^a   Najafi, Iraj ^b   Hedayati, Mehdi ^c   Rahmani, Leila ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Shafa Clinic   (Iran)

Author keywords

Cardiovascular disease; Ginger; Lipids; Lipoproteins; Peritoneal dialysis

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD BIOCHEMISTRY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GINGER; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMISTRY; DIETARY SUPPLEMENT; DRUG EFFECTS; HYPERLIPIDEMIAS; IRAN; KIDNEY FAILURE, CHRONIC; REGISTER;

ADULT; AGED; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GINGER; HUMANS; HYPERLIPIDEMIAS; IRAN; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; REGISTRIES;

EID: 84961572828     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2015.00006     Document Type: Article

References (44)

1. Singh AK, Brenner BM. Dialysis in the treatment of renal failure. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005:1663–7.
2. Jungers P, Khoa TN, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: a multicentric study in the IIe de France district. Nephrol Dial Transplant 1999; 14(4):898–902.
3. Wanner C. Altered lipid metabolism and serum lipids in renal disease and renal failure. In: Kopple JD, Massary SG, eds. Kopple and Massary’s Nutritional Management of Renal Disease. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004:42–55.
4. O’Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27(1):84–91.
5. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992; 38(5):271–6.
6. Fytili CI, Progia EG, Panagoutsos SA, Thodis ED, Passadakis PS, Sombolos KI, et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002; 24(5):623–30.
7. Kimak E, Berger B, Solski J, Janicka L, Ksiazek A. Comparison of lipid and lipoprotein profiles in long-term chronic ambulatory peritoneal dialysis (CAPD) in elderly patients with chronic renal failure (CRF). Int Urol Nephrol 2002; 33(1):203–4.
8. Ong-Ajyooth L, Sirisalee K, Shayakul C, Vareesangthip K, Vasuvattakul S, Vanichakarn S, et al. Comparison of lipid abnormalities in continuous ambulatory peritoneal dialysis and hemodialysis patients. Transplant Proc 1994; 26(4):2077–9.
9. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995; 15(8):342–7.
10. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2):S205–9.
11. Prichard S. Major and minor risk factors for cardiovascular disease in peritoneal dialysis. Perit Dial Int 2000; 20(Suppl 2):S154–9.
12. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26(5):523–39.
13. Leong DJ, Choudhury M, Hirsh DM, Hardin JA, Cobelli NJ, Sun HB. Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis. Int J Mol Sci 2013; 14(11):23063–85.
14. Nicoll R, Henein MY. Ginger (Zingiber officinale Roscoe): a hot remedy for cardiovascular disease? Int J Cardiol 2009; 131(3):408–9.
15. Arablou T, Aryaeian N, Valizadeh M, Sharifi F, Hosseini A, Djalali M. The effect of ginger consumption on glycemic status, lipid profile and some inflammatory markers in patients with type 2 diabetes mellitus. Int J Food Sci Nutr 2014; 65(4):515–20.
16. Mahluji S, Attari VE, Mobasseri M, Payahoo L, Ostadrahimi A, Golzari SE. Effects of ginger (Zingiber officinale) on plasma glucose level, HbA1c and insulin sensitivity in type 2 diabetic patients. Int J Food Sci Nutr 2013; 64(6):682–6.
17. Andallu B, Radhika B, Suryakantham V. Effect of aswagandha, ginger and mulberry on hyperglycemia and hyperlipidemia. Plant Food Hum Nutr 2003; 58(3):1–7.
18. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparation ultracentrifuge. Clin Chem 1972; 18(6):499–502.
19. rd ed. New York: Springer; 2009:469–503.
20. rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:281–96.
21. rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:361–72.
22. th ed. Philadelphia: Williams & Wilkins; 2001:1346–56.
23. th ed. Missouri: Elsevier/Saunders; 2012:746.
24. rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:405–10.
25. rd ed. Amsterdam: Academic Press; 2013:21.
26. th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:663.
27. Winter BK, Fiskum G, Gallo LL. Effect of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 1995; 72(5): 1173–9.
28. Bhandari U, Kanojia R, Pillai KK. Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol 2005; 97(2):227–30.
29. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R, Ali M. Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. Br J Nutr 2006; 96(4):660–6.
30. ElRokh El-SM, Yassin NA, El-Shenawy SM, Ibrahim BM. Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats. Inflammopharmacology 2010; 18(6):309–15.
31. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997; 56(5):379–84.
32. Imani H, Tabibi H, Najafi I, Atabak S, Hedayati M, Rahmani L. Effects of ginger on serum glucose, advanced glycation end products and inflammation in peritoneal dialysis patients. Nutrition 2015; [In press].
33. Son MJ, Miura Y, Yagasaki K. Mechanisms for antidiabetic effect of gingerol in cultured cells and obese diabetic model mice. Cytotechnology 2015; [In press].
34. Li Y, Tran VH, Duke CC, Roufogalis BD. Gingerols of Zingiber officinale enhance glucose uptake by increasing cell surface GLUT4 in cultured L6 myotubes. Planta Med 2012; 78(14):1549–55.
35. Mahluji S, Ostadrahimi A, Mobasseri M, Ebrahimzade Attari V, Payahoo L. Anti-inflammatory effects of Zingiber officinale in type 2 diabetic patients. Adv Pharm Bull 2013; 3(2):273–6.
36. Al-Noory AS, Amreen AN, Hymoor S. Antihyperlipidemic effects of ginger extracts in alloxan-induced diabetes and propylthiouracil-induced hypothyroidism in rats. Pharmacognosy Res 2013; 5(3):157–61.
37. Heimburger O, Stenvinkel P, Berglund L, Tranaus A, Lindholm B. Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996; 72(2):135–44.
38. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998; 82(9A):34Q–46Q.
39. Spinler SA, Cziraky MJ. Lipoprotein (a): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994; 28(3):343–51.
40. Djurovic S, Berg K. Epidemiology of Lp (a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52(5):281–92.
41. Dahlen GH, Stenlund H. Lp (a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997; 52(5):272–80.
42. Boonmark NW, Lawn RM. The lysine-binding function of Lp (a). Clin Genet 1997; 52(5):355–60.
43. Ross EA, Shah GM, Kashyap ML. Elevated plasma lipoprotein (a) levels and hypoalbuminemia in peritoneal dialysis patients. Int J Artif Organs 1995; 18(12):751–6.
44. Anwar N, Bhatnagar D, Short CD, Mackness MI, Durrington PN, Prais H, et al. Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8(1):71–4.